Patient-reported barriers to accepting a technological adherence package in the MAGNIFY trial

A Dickens; D Halpin; V Carter; D Skinner; K Beeh; J Chalmers; A Clark; N Hannan; A Kaplan; K Kostikas; H Pinnock; N Roche; O Usmani; J F V Boven; P Mastoridis; K Mezzi; S Davis; D Price

doi:10.1183/13993003.congress-2022.3402

Abstract

Introduction: COPD exacerbations lead to increased mortality and disease progression. Maintenance inhaled therapies can reduce exacerbation risk amongst COPD patients, but non-adherence reportedly ranges from 20-60% in this population. The ongoing cluster randomised trial MAGNIFY is investigating the use of technological adherence support as a solution to this problem, but there is little evidence regarding patients’ willingness to accept such devices.Aims and objectives: To explore patient-reported barriers to accepting a technological adherence package.Methods: COPD patients were eligible for MAGNIFY if aged 40 years or above, with ≥2 moderate/severe exacerbations in the last two years and with ≤50% adherence to mono/dual therapy. Eligible patients received a phone call from a pharmacist who conducted a remote patient review and invited them to use the digital support package, comprising an Ultibro Breezhaler and adherence support technology. Patients declining the package were asked to provide reasons.Results: Out of 331 patients clinically suitable for the adherence package, 113 (34.1%) declined the adherence package. Reasons for declining included: no smartphone/not compatible phone (n=89), unwilling to change inhaler (n=8), unwilling to use inhalers regularly (n=5), life events (n=2), another health condition (n=1), no reason (n=8).Conclusions: Most patients declined the adherence package for practical reasons, such as lacking a compatible smartphone, rather than unwillingness to use technology. Though this is interim data from a single trial, it suggests that technophobia may not be an important barrier to patients accepting technological adherence support.FootnotesCite this article as Eur Respir J 2022; 60: Suppl. 66, 3402.This article was presented at the 2022 ERS International Congress, in session “-”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

Original language	English
Article number	3402
Journal	European Respiratory Journal
Volume	60
Issue number	Suppl. 66
DOIs	https://doi.org/10.1183/13993003.congress-2022.3402
Publication status	Published - 4 Sep 2022
Event	European Respiratory Society (ERS) International Congress. - FIRA Barcelona Gran Via Congress Centre, Barcelona, Spain Duration: 4 Sep 2022 → 6 Sep 2022 https://www.ersnet.org/congress-and-events/congress/

Access to Document

10.1183/13993003.congress-2022.3402Licence: Unspecified

http://erj.ersjournals.com/content/60/suppl_66/3402.abstract

Cite this

Dickens, A., Halpin, D., Carter, V., Skinner, D., Beeh, K., Chalmers, J., Clark, A., Hannan, N., Kaplan, A., Kostikas, K., Pinnock, H., Roche, N., Usmani, O., Boven, J. F. V., Mastoridis, P., Mezzi, K., Davis, S., & Price, D. (2022). Patient-reported barriers to accepting a technological adherence package in the MAGNIFY trial. European Respiratory Journal, 60(Suppl. 66), [3402]. https://doi.org/10.1183/13993003.congress-2022.3402

Dickens, A, Halpin, D, Carter, V, Skinner, D, Beeh, K, Chalmers, J, Clark, A, Hannan, N, Kaplan, A, Kostikas, K, Pinnock, H, Roche, N, Usmani, O, Boven, JFV, Mastoridis, P, Mezzi, K, Davis, S & Price, D 2022, 'Patient-reported barriers to accepting a technological adherence package in the MAGNIFY trial', European Respiratory Journal, vol. 60, no. Suppl. 66, 3402. https://doi.org/10.1183/13993003.congress-2022.3402

@article{5cf0e6f0267743b59a1d04b02f6877a5,

title = "Patient-reported barriers to accepting a technological adherence package in the MAGNIFY trial",

abstract = "Introduction: COPD exacerbations lead to increased mortality and disease progression. Maintenance inhaled therapies can reduce exacerbation risk amongst COPD patients, but non-adherence reportedly ranges from 20-60% in this population. The ongoing cluster randomised trial MAGNIFY is investigating the use of technological adherence support as a solution to this problem, but there is little evidence regarding patients{\textquoteright} willingness to accept such devices.Aims and objectives: To explore patient-reported barriers to accepting a technological adherence package.Methods: COPD patients were eligible for MAGNIFY if aged 40 years or above, with ≥2 moderate/severe exacerbations in the last two years and with ≤50% adherence to mono/dual therapy. Eligible patients received a phone call from a pharmacist who conducted a remote patient review and invited them to use the digital support package, comprising an Ultibro Breezhaler and adherence support technology. Patients declining the package were asked to provide reasons.Results: Out of 331 patients clinically suitable for the adherence package, 113 (34.1%) declined the adherence package. Reasons for declining included: no smartphone/not compatible phone (n=89), unwilling to change inhaler (n=8), unwilling to use inhalers regularly (n=5), life events (n=2), another health condition (n=1), no reason (n=8).Conclusions: Most patients declined the adherence package for practical reasons, such as lacking a compatible smartphone, rather than unwillingness to use technology. Though this is interim data from a single trial, it suggests that technophobia may not be an important barrier to patients accepting technological adherence support.FootnotesCite this article as Eur Respir J 2022; 60: Suppl. 66, 3402.This article was presented at the 2022 ERS International Congress, in session “-”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).",

author = "A Dickens and D Halpin and V Carter and D Skinner and K Beeh and J Chalmers and A Clark and N Hannan and A Kaplan and K Kostikas and H Pinnock and N Roche and O Usmani and Boven, {J F V} and P Mastoridis and K Mezzi and S Davis and D Price",

year = "2022",

month = sep,

day = "4",

doi = "10.1183/13993003.congress-2022.3402",

language = "English",

volume = "60",

journal = "European Respiratory Journal",

issn = "0903-1936",

publisher = "European Respiratory Society",

number = "Suppl. 66",

note = "European Respiratory Society (ERS) International Congress., ERS International Congress 2022 ; Conference date: 04-09-2022 Through 06-09-2022",

url = "https://www.ersnet.org/congress-and-events/congress/",

}

TY - JOUR

T1 - Patient-reported barriers to accepting a technological adherence package in the MAGNIFY trial

AU - Dickens, A

AU - Halpin, D

AU - Carter, V

AU - Skinner, D

AU - Beeh, K

AU - Chalmers, J

AU - Clark, A

AU - Hannan, N

AU - Kaplan, A

AU - Kostikas, K

AU - Pinnock, H

AU - Roche, N

AU - Usmani, O

AU - Boven, J F V

AU - Mastoridis, P

AU - Mezzi, K

AU - Davis, S

AU - Price, D

PY - 2022/9/4

Y1 - 2022/9/4

N2 - Introduction: COPD exacerbations lead to increased mortality and disease progression. Maintenance inhaled therapies can reduce exacerbation risk amongst COPD patients, but non-adherence reportedly ranges from 20-60% in this population. The ongoing cluster randomised trial MAGNIFY is investigating the use of technological adherence support as a solution to this problem, but there is little evidence regarding patients’ willingness to accept such devices.Aims and objectives: To explore patient-reported barriers to accepting a technological adherence package.Methods: COPD patients were eligible for MAGNIFY if aged 40 years or above, with ≥2 moderate/severe exacerbations in the last two years and with ≤50% adherence to mono/dual therapy. Eligible patients received a phone call from a pharmacist who conducted a remote patient review and invited them to use the digital support package, comprising an Ultibro Breezhaler and adherence support technology. Patients declining the package were asked to provide reasons.Results: Out of 331 patients clinically suitable for the adherence package, 113 (34.1%) declined the adherence package. Reasons for declining included: no smartphone/not compatible phone (n=89), unwilling to change inhaler (n=8), unwilling to use inhalers regularly (n=5), life events (n=2), another health condition (n=1), no reason (n=8).Conclusions: Most patients declined the adherence package for practical reasons, such as lacking a compatible smartphone, rather than unwillingness to use technology. Though this is interim data from a single trial, it suggests that technophobia may not be an important barrier to patients accepting technological adherence support.FootnotesCite this article as Eur Respir J 2022; 60: Suppl. 66, 3402.This article was presented at the 2022 ERS International Congress, in session “-”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

AB - Introduction: COPD exacerbations lead to increased mortality and disease progression. Maintenance inhaled therapies can reduce exacerbation risk amongst COPD patients, but non-adherence reportedly ranges from 20-60% in this population. The ongoing cluster randomised trial MAGNIFY is investigating the use of technological adherence support as a solution to this problem, but there is little evidence regarding patients’ willingness to accept such devices.Aims and objectives: To explore patient-reported barriers to accepting a technological adherence package.Methods: COPD patients were eligible for MAGNIFY if aged 40 years or above, with ≥2 moderate/severe exacerbations in the last two years and with ≤50% adherence to mono/dual therapy. Eligible patients received a phone call from a pharmacist who conducted a remote patient review and invited them to use the digital support package, comprising an Ultibro Breezhaler and adherence support technology. Patients declining the package were asked to provide reasons.Results: Out of 331 patients clinically suitable for the adherence package, 113 (34.1%) declined the adherence package. Reasons for declining included: no smartphone/not compatible phone (n=89), unwilling to change inhaler (n=8), unwilling to use inhalers regularly (n=5), life events (n=2), another health condition (n=1), no reason (n=8).Conclusions: Most patients declined the adherence package for practical reasons, such as lacking a compatible smartphone, rather than unwillingness to use technology. Though this is interim data from a single trial, it suggests that technophobia may not be an important barrier to patients accepting technological adherence support.FootnotesCite this article as Eur Respir J 2022; 60: Suppl. 66, 3402.This article was presented at the 2022 ERS International Congress, in session “-”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

U2 - 10.1183/13993003.congress-2022.3402

DO - 10.1183/13993003.congress-2022.3402

M3 - Abstract

VL - 60

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - Suppl. 66

M1 - 3402

T2 - European Respiratory Society (ERS) International Congress.

Y2 - 4 September 2022 through 6 September 2022

ER -

Patient-reported barriers to accepting a technological adherence package in the MAGNIFY trial

Abstract

Access to Document

Fingerprint

Cite this